{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:55Z","timestamp":1792790455036,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA000069"],"award-info":[{"award-number":["DA000069"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","id":[{"id":"https:\/\/ror.org\/05p26gw61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41380-021-01093-2","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T01:03:22Z","timestamp":1618448602000},"page":"6704-6722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":265,"title":["Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-0151","authenticated-orcid":false,"given":"Jordi","family":"Bonaventura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan L.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"S\u00e1nchez-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Fredriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-962X","authenticated-orcid":false,"given":"David R.","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-3319","authenticated-orcid":false,"given":"Yavin","family":"Shaham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-4917","authenticated-orcid":false,"given":"Michael","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/aps.2016.5","volume":"37","author":"M Gao","year":"2016","unstructured":"Gao M, Rejaei D, Liu H. Ketamine use in current clinical practice. Acta Pharm Sin. 2016;37:865\u201372.","journal-title":"Acta Pharm Sin"},{"key":"1093_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793\u2013802.","journal-title":"Arch Gen Psychiatry"},{"key":"1093_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","volume":"71","author":"CA Zarate","year":"2012","unstructured":"Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik AL, et al. Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939\u201346.","journal-title":"Biol Psychiatry"},{"key":"1093_CR6","doi-asserted-by":"crossref","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al., Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018;25:1592\u20131603.","DOI":"10.1038\/s41380-018-0256-5"},{"key":"1093_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","volume":"173","author":"JB Singh","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly EJ, Boer PD, Cooper K, Lim P, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816\u201326.","journal-title":"Am J Psychiatry"},{"key":"1093_CR8","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134\u201342.","journal-title":"Am J Psychiatry"},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","volume":"67","author":"M aan het Rot","year":"2010","unstructured":"aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139\u201345.","journal-title":"Biol Psychiatry"},{"key":"1093_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2009.04.003","volume":"105","author":"LP Carter","year":"2009","unstructured":"Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 2009;105:14\u201325.","journal-title":"Drug Alcohol Depend"},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s12264-016-0081-2","volume":"32","author":"W Zhu","year":"2016","unstructured":"Zhu W, Ding Z, Zhang Yinan, Shi Jie, Hashimoto Kenji, Lu Lin. Risks associated with misuse of ketamine as a rapid-acting antidepressant. Neurosci Bull. 2016;32:557\u201364.","journal-title":"Neurosci Bull"},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fnana.2013.00023","volume":"7","author":"C Wang","year":"2013","unstructured":"Wang C, Zheng D, Xu J, Lam W, Yew DT. Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat. 2013;7:23.","journal-title":"Front Neuroanat"},{"key":"1093_CR13","unstructured":"US Food and Drug Administration, FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic. 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified."},{"key":"1093_CR14","unstructured":"Janssen Announces U.S. FDA Approval of SPRAVATO\u00ae (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior. 2020 https:\/\/www.prnewswire.com\/news-releases\/janssen-announces-us-fda-approval-of-spravato-esketamine-ciii-nasal-spray-to-treat-depressive-symptoms-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior-301104437.html."},{"key":"1093_CR15","first-page":"977","volume":"6","author":"EH Turner","year":"2019","unstructured":"Turner EH. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet. 2019;6:977\u20139.","journal-title":"Lancet"},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1176\/appi.ajp.2019.19040423","volume":"176","author":"AF Schatzberg","year":"2019","unstructured":"Schatzberg AF. A word to the wise about intranasal ketamine. Am J Psychiatry. 2019;176:422\u20134.","journal-title":"Am J Psychiatry"},{"key":"1093_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.136","volume":"5","author":"C Yang","year":"2015","unstructured":"Yang C, Shirayama Y, Zhang J-c, Ren Q, Yao W, Ma M, et al. (R)-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632.","journal-title":"Transl Psychiatry"},{"key":"1093_CR18","doi-asserted-by":"crossref","unstructured":"Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. 2020;271:577\u201382.","DOI":"10.1007\/s00406-020-01110-5"},{"key":"1093_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharm Rev. 2018;70:621\u201360.","journal-title":"Pharm Rev"},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","volume":"36","author":"CF Zorumski","year":"2016","unstructured":"Zorumski CF, Izumi Y, Mennerick S. Ketamine: NMDA receptors and beyond. J Neurosci. 2016;36:11158\u201364.","journal-title":"J Neurosci"},{"key":"1093_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1471-4159.2011.07361.x","volume":"119","author":"A Gupta","year":"2011","unstructured":"Gupta A, Devi LA, Gomes I. Potentiation of \u03bc-opioid receptor-mediated signaling by ketamine. J Neurochem 2011;119:294\u2013302.","journal-title":"J Neurochem"},{"key":"1093_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","volume":"210","author":"CL Nemeth","year":"2010","unstructured":"Nemeth CL, Paine TA, Rittiner JE, B\u00e9guin C, Carroll FI, Roth BL, et al. Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology. 2010;210:263\u20134.","journal-title":"Psychopharmacology"},{"key":"1093_CR23","first-page":"383","volume":"230","author":"Y Itzhak","year":"1984","unstructured":"Itzhak Y, Simon EJ. A novel phencyclidine analog interacts selectively with mu opioid receptors. J Pharmacol Exp Ther. 1984;230:383\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"1093_CR24","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1021\/jm00061a009","volume":"36","author":"XS He","year":"1993","unstructured":"He XS, Raymon LP, Mattson MV, Eldefrawi ME, de Costa BR. Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-binding sites. J Med Chem.1993;36:1188\u201393.","journal-title":"J Med Chem."},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/0091-3057(89)90020-8","volume":"32","author":"I Chaudieu","year":"1989","unstructured":"Chaudieu I, Vignon J, Chicheportiche M, Kamenka JM, Trouiller G, Chicheportiche R. Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs. Pharmacol Biochem Behav. 1989;32:699\u2013705.","journal-title":"Pharmacol Biochem Behav"},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/sj.mp.4001682","volume":"10","author":"P Seeman","year":"2005","unstructured":"Seeman P, Ko F, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry. 2005;10:877\u201383.","journal-title":"Mol Psychiatry"},{"key":"1093_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00213-010-2062-x","volume":"214","author":"M De Luca","year":"2011","unstructured":"De Luca M, Badiani A. Ketamine self-administration in the rat: evidence for a critical role of setting. Psychopharmacology. 2011;214:549\u201356.","journal-title":"Psychopharmacology"},{"key":"1093_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","volume":"107","author":"CAJ Morgan","year":"2012","unstructured":"Morgan CAJ, Curran H. Independent scientific committee on drugs, ketamine use: a review. Addiction. 2012;107:27\u201328.","journal-title":"Addiction"},{"key":"1093_CR29","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1007\/s00213-014-3451-3","volume":"231","author":"TM Hillhouse","year":"2014","unstructured":"Hillhouse TM, Porter JH, Negus SS. Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats. Psychopharmacology. 2014;231:2705\u201316.","journal-title":"Psychopharmacology"},{"key":"1093_CR30","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00213-014-3543-0","volume":"231","author":"C Yang","year":"2014","unstructured":"Yang C, Hashimoto K. Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology. 2014;231:2041\u20132.","journal-title":"Psychopharmacology"},{"key":"1093_CR31","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s00213-014-3544-z","volume":"231","author":"TM Hillhouse","year":"2014","unstructured":"Hillhouse TM, Porter JH, Negus SS. Reply to: Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology. 2014;231:2743\u20134.","journal-title":"Psychopharmacology"},{"key":"1093_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0149-7634(05)80089-2","volume":"15","author":"JV Brady","year":"1991","unstructured":"Brady JV. Animal models for assessing drugs of abuse. Neurosci Biobehav Rev. 1991;15:35\u201343.","journal-title":"Neurosci Biobehav Rev"},{"key":"1093_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jad.2020.01.141","volume":"266","author":"GE Hunt","year":"2020","unstructured":"Hunt GE, Malhi GS, Xiong Lai HM, Cleary M. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis. J Affect Disord. 2020;266:288\u2013304.","journal-title":"J Affect Disord"},{"key":"1093_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1037\/0033-295X.94.4.469","volume":"94","author":"RA Wise","year":"1987","unstructured":"Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987;94:469\u201392.","journal-title":"Psychol Rev"},{"key":"1093_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s002130000569","volume":"153","author":"MT Bardo","year":"2000","unstructured":"Bardo MT, Bevins RA. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology. 2000;153:31\u201343.","journal-title":"Psychopharmacology"},{"key":"1093_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev.pa.09.040169.002411","volume":"9","author":"CR Schuster","year":"1969","unstructured":"Schuster CR, Thompson T. Self administration of and behavioral dependence on drugs. Annu Rev Pharmacol. 1969;9:483\u2013502.","journal-title":"Annu Rev Pharmacol"},{"key":"1093_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0969-8051(96)00186-2","volume":"24","author":"CY Shiue","year":"1997","unstructured":"Shiue CY, et al. Carbon-11 labelled ketamine-synthesis, distribution in mice and PET studies in baboons. Nucl Med Biol. 1997;24:145\u201350.","journal-title":"Nucl Med Biol."},{"key":"1093_CR38","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/0969-8051(94)90081-7","volume":"21","author":"P Hartvig","year":"1994","unstructured":"Hartvig P, Valtysson J, Antoni G, Westerberg G, L\u00e5ngstr\u00f6m B, Ratti Moberg E. et al. Brain kinetics of (R)- and (S)-[N-methyl-11C]ketamine in the rhesus monkey studied by positron emission tomography (PET). Nucl Med Biol.1994;21:927\u201334.","journal-title":"Nucl Med Biol."},{"key":"1093_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1528-1157.1999.tb01985.x","volume":"40","author":"E Kumlien","year":"1999","unstructured":"Kumlien E, Hartvig P, Valind S, Oye I, Tedroff J, L\u00e5ngstr\u00f6m B. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy. Epilepsia. 1999;40:30\u20137.","journal-title":"Epilepsia"},{"key":"1093_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0014-2999(00)00263-6","volume":"397","author":"F Murray","year":"2000","unstructured":"Murray F, Kennedy J, Hutson PH, Elliot J, Huscroft I, Mohnen K, et al. Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur J Pharmacol. 2000;397:263\u201370.","journal-title":"Eur J Pharmacol"},{"key":"1093_CR41","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1152\/jn.00252.2009","volume":"102","author":"BE Herring","year":"2009","unstructured":"Herring BE, Xie Z, Marks J, Fox AP. Isoflurane Inhibits the neurotransmitter release machinery. J Neurophysiol. 2009;102:1265\u201373.","journal-title":"J Neurophysiol."},{"key":"1093_CR42","doi-asserted-by":"publisher","first-page":"7942","DOI":"10.1016\/j.chroma.2010.06.028","volume":"1217","author":"S Portmann","year":"2010","unstructured":"Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J Chromatogr A. 2010;1217:7942\u20138.","journal-title":"J Chromatogr A"},{"key":"1093_CR43","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0006-8993(97)01390-5","volume":"787","author":"GE Duncan","year":"1998","unstructured":"Duncan GE, Moy SS, Knapp DJ, Mueller RA, Breese GR. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res. 1998;787:181\u201390.","journal-title":"Brain Res"},{"key":"1093_CR44","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0893-133X(99)00127-X","volume":"22","author":"S Miyamoto","year":"2000","unstructured":"Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology. 2000;22:400\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"1093_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41583-018-0013-4","volume":"19","author":"EA Murray","year":"2018","unstructured":"Murray EA, Rudebeck PH. Specializations for reward-guided decision-making in the primate ventral prefrontal cortex. Nat Rev Neurosci. 2018;19:404\u201317.","journal-title":"Nat Rev Neurosci."},{"key":"1093_CR46","doi-asserted-by":"crossref","unstructured":"Hare BD, Duman RS. Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions. Mol Psychiatry. 2020;25:2742\u201358.","DOI":"10.1038\/s41380-020-0685-9"},{"key":"1093_CR47","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1073\/pnas.1916570117","volume":"117","author":"ME Klein","year":"2020","unstructured":"Klein ME, Chandra J, Sheriff S, Malinow R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. PNAS. 2020;117:2656\u201362.","journal-title":"PNAS"},{"key":"1093_CR48","doi-asserted-by":"crossref","unstructured":"Jacobson ML, Simmons SC, Wulf HA, Cheng H, Feng Y, Nugent FS, et al., Protracted effects of ketamine require immediate kappa opioid receptor activation and long\u2010lasting desensitization. FASEB J. 2020;34:1\u20131.","DOI":"10.1096\/fasebj.2020.34.s1.04214"},{"key":"1093_CR49","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175:1205\u201315.","journal-title":"Am J Psychiatry"},{"key":"1093_CR50","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","volume":"24","author":"NR Williams","year":"2019","unstructured":"Williams NR, Heifets BD, Bentzley BS, Blasey C, Sudheimer KD, Hawkins J, et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry. 2019;24:1779\u201386.","journal-title":"Mol Psychiatry"},{"key":"1093_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0165-6147(02)00027-5","volume":"24","author":"G Milligan","year":"2003","unstructured":"Milligan G. Principles: extending the utility of [35S]GTP gamma S binding assays. Trends Pharm Sci. 2003;24:87\u201390.","journal-title":"Trends Pharm Sci"},{"key":"1093_CR52","first-page":"840","volume":"299","author":"LJ Vogt","year":"2001","unstructured":"Vogt LJ, Sim-Selley LJ, Childers SR, Wiley RG, Vogt BA. Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex. J Pharm Exp Ther. 2001;299:840\u20138.","journal-title":"J Pharm Exp Ther"},{"key":"1093_CR53","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/npp.2013.76","volume":"38","author":"HA Tejeda","year":"2013","unstructured":"Tejeda HA, Counotte DS, Oh E, Ramamoorthy S, Schultz-Kuszak KN, B\u00e4ckman CM, et al. Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion. Neuropsychopharmacology. 2013;38:1770\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"1093_CR54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0165-0173(93)90008-N","volume":"18","author":"PW Kalivas","year":"1993","unstructured":"Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Brain Res Rev. 1993;18:75\u2013113.","journal-title":"Brain Res Brain Res Rev"},{"key":"1093_CR55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.ps.40.020189.001203","volume":"40","author":"RA Wise","year":"1989","unstructured":"Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol. 1989;40:191\u2013225.","journal-title":"Annu Rev Psychol"},{"key":"1093_CR56","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","volume":"12","author":"SW Johnson","year":"1992","unstructured":"Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12:483\u20138.","journal-title":"J Neurosci"},{"key":"1093_CR57","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1073\/pnas.0511159103","volume":"103","author":"EB Margolis","year":"2006","unstructured":"Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL. \u03ba opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. PNAS. 2006;103:2938\u201342.","journal-title":"PNAS"},{"key":"1093_CR58","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrn3104","volume":"12","author":"A Badiani","year":"2011","unstructured":"Badiani A, Belin D, Epstein D, Calu D, Shaham Y. Opiate versus psychostimulant addiction: the differences do matter. Nat Rev Neurosci. 2011;12:685\u2013700.","journal-title":"Nat Rev Neurosci"},{"key":"1093_CR59","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","volume":"267","author":"K Hashimoto","year":"2017","unstructured":"Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H. Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci. 2017;267:173\u20136.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1093_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/syn.20734","volume":"64","author":"M Slifstein","year":"2011","unstructured":"Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J, et al. Striatal and extrastriatal dopamine release measured with PET and [18F]fallypride. Synapse. 2011;64:350\u201362.","journal-title":"Synapse"},{"key":"1093_CR61","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1007\/s00213-017-4660-3","volume":"234","author":"SA McDougall","year":"2017","unstructured":"McDougall SA, Moran AE, Baum TJ, Apodaca MG, Real V. Effects of ketamine on the unconditioned and conditioned locomotor activity of preadolescent and adolescent rats: impact of age, sex, and drug dose. Psychopharmacology. 2017;234:2683\u201396.","journal-title":"Psychopharmacology"},{"key":"1093_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0006-8993(82)91123-4","volume":"243","author":"RF Mucha","year":"1982","unstructured":"Mucha RF, van der Kooy D D, O\u2019Shaughnessy M, Bucenieks P. Drug reinforcement studied by the use of place conditioning in rat. Brain Res. 1982;243:91\u2013105.","journal-title":"Brain Res"},{"key":"1093_CR63","doi-asserted-by":"crossref","unstructured":"Yokel RF, Intravenous self-administration: response rates, the effects of pharmacological challenges, and drug preference. In: Bozarth MA, editor. Methods of assessing the reinforcing properties of abused drugs. New York: Springer-Verlag; 1987. p. 1\u201334","DOI":"10.1007\/978-1-4612-4812-5_1"},{"key":"1093_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","volume":"66","author":"NR Richardson","year":"1996","unstructured":"Richardson NR, Roberts DC. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods. 1996;66:1\u201311.","journal-title":"J Neurosci Methods"},{"key":"1093_CR65","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41583-020-0378-z","volume":"21","author":"M Venniro","year":"2020","unstructured":"Venniro M, Banks ML, Heilig M, Epstein DH, Shaham Y. Improving translation of animal models of addiction and relapse by reverse translation. Nat Rev Neurosci Brain Res. 2020;21:625\u2013623.","journal-title":"Nat Rev Neurosci Brain Res"},{"key":"1093_CR66","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","volume":"76","author":"G Yoon","year":"2019","unstructured":"Yoon G, Petrakis IL, Krystal JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry. 2019;76:337\u20138.","journal-title":"JAMA Psychiatry"},{"key":"1093_CR67","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/jamapsychiatry.2019.0766","volume":"76","author":"BD Heifets","year":"2019","unstructured":"Heifets BD, Williams NR, Bentzley BS, Schatzberg AF. Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine\u2019s Antidepressant Effect. JAMA Psychiatry. 2019;76:657\u20139.","journal-title":"JAMA Psychiatry"},{"key":"1093_CR68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","volume":"1562","author":"DF Pacheco","year":"2014","unstructured":"Pacheco DF, Romero T, Duarte I. Central antinociception induced by ketamine is mediated by endogenous opioids and \u03bc- and \u03b4-opioid receptors. Brain Res. 2014;1562:69\u201375.","journal-title":"Brain Res"},{"key":"1093_CR69","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1111\/bph.14683","volume":"176","author":"P Zanos","year":"2019","unstructured":"Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, et al. (R)\u2010Ketamine exerts antidepressant actions partly via conversion to (2R,6R)\u2010hydroxynorketamine, while causing adverse effects at sub\u2010anaesthetic doses. Br J Pharmacol. 2019;176:2573\u201392.","journal-title":"Br J Pharmacol"},{"key":"1093_CR70","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature25509","volume":"14","author":"Y Yang","year":"2018","unstructured":"Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;14:317\u201322.","journal-title":"Nature"},{"key":"1093_CR71","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","volume":"19","author":"K Zhang","year":"2018","unstructured":"Zhang K, Hashimoto K. An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother. 2018;19:83\u201392.","journal-title":"Expert Rev Neurother"},{"key":"1093_CR72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","volume":"7","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol. 1997;7:25\u201338.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1093_CR73","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.biopsych.2013.02.008","volume":"15","author":"PJ Carlson","year":"2013","unstructured":"Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, et al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry 2013;15:1213\u201321.","journal-title":"Biol Psychiatry"},{"key":"1093_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/syn.22126","volume":"73","author":"Y Masaki","year":"2019","unstructured":"Masaki Y, Kashiwagi Y, Watabe H, Abe K. (R)\u2010 and (S)\u2010ketamine induce differential fMRI responses in conscious rats. Synapse. 2019;73:e22126.","journal-title":"Synapse"},{"key":"1093_CR75","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/B978-0-12-420118-7.00009-3","volume":"69","author":"RR Matsumoto","year":"2014","unstructured":"Matsumoto RR, Nguyen L, Kaushal N, Robson MJ. Sigma (\u03c3) receptors as potential therapeutic targets to mitigate psychostimulant effects. Adv Pharmacol 2014;69:323\u201386.","journal-title":"Adv Pharmacol"},{"key":"1093_CR76","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0165-0173(91)90007-U","volume":"16","author":"PW Kalivas","year":"1991","unstructured":"Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev. 1991;16:223\u201344.","journal-title":"Brain Res Rev"},{"key":"1093_CR77","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jad.2020.03.040","volume":"269","author":"Y Tan","year":"2020","unstructured":"Tan Y, Hashimoto K. Risk of psychosis after repeated intermittent administration of (S)-ketamine, but not (R)-ketamine, in mice. J Affect Disord. 2020;269:198\u2013200.","journal-title":"J Affect Disord"},{"key":"1093_CR78","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","volume":"181","author":"L Chang","year":"2019","unstructured":"Chang L, Zhang K, Pu Y, Qu Y, Wang S, Xiong Z, et al. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav. 2019;181:53\u20139.","journal-title":"Pharmacol Biochem Behav"},{"key":"1093_CR79","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1749-6632.1992.tb25984.x","volume":"654","author":"CP O\u2019Brien","year":"1992","unstructured":"O\u2019Brien CP, Childress AR, McLellan AT, Ehrman R. Classical conditioning in drug-dependent humans. Ann N. Y Acad Sci. 1992;654:400\u201315.","journal-title":"Ann N. Y Acad Sci"},{"key":"1093_CR80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob. S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm"},{"key":"1093_CR81","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/sj.jcbfm.9600359","volume":"27","author":"ED Morris","year":"2007","unstructured":"Morris ED, Yoder KK. Positron emission tomography displacement sensitivity: predicting binding potential change for positron emission tomography tracers based on their kinetic characteristics. J Cereb Blood Flow Metab. 2007;27:606\u201317.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1093_CR82","unstructured":"US Food and Drug Administration, Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 2019. https:\/\/www.fda.gov\/advisory-committees\/february-12-2019-joint-meeting-psychopharmacologic-drugs-advisory-committee-pdac-and-drug-safety-and#event-materials."},{"key":"1093_CR83","doi-asserted-by":"publisher","first-page":"172927","DOI":"10.1016\/j.pbb.2020.172927","volume":"194","author":"JM Witkin","year":"2020","unstructured":"Witkin JM, Kranzler J, Kaniecki K, Popik P, Smith JL, Hashimoto K, et al. R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder. Pharmacol Biochem Behav 2020;194:172927.","journal-title":"Pharmacol Biochem Behav"},{"key":"1093_CR84","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI126912","volume":"129","author":"N-S Cai","year":"2019","unstructured":"Cai N-S, Quiroz C, Bonaventura J, Bonifazi A, Cole TO, Purks J. Opioid\u2013galanin receptor heteromers mediate the dopaminergic effects of opioids. J Clin Investig. 2019;129:2730\u201344.","journal-title":"J Clin Investig"},{"key":"1093_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12236-z","volume":"10","author":"J Bonaventura","year":"2019","unstructured":"Bonaventura J, Eldridge MAG, Hu F, Gomez JL, Sanchez-Soto M, Abramyan A, et al. High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nat Commun. 2019;10:4627.","journal-title":"Nat Commun"},{"key":"1093_CR86","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41386-020-0602-6","volume":"45","author":"I Fredriksson I","year":"2020","unstructured":"Fredriksson I I, Applebey SV, Minier-Toribio A, Shekara A A, Bosser JM, Shaham Y Y. Effect of the dopamine stabilizer (-)-OSU6162 on potentiated incubation of opioid craving after electric barrier-induced voluntary abstinence. Neuropsychopharmacology. 2020;45:770\u20139.","journal-title":"Neuropsychopharmacology"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01093-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01093-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01093-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T07:03:37Z","timestamp":1675148617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-021-01093-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1038\/s41380-021-01093-2","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"27 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. CAZ is listed as co-inventor on a patent for the use of (2R,6R)- hydroxynorketamine, (S)-dehydronorketamine, and other stereo- isomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and posttraumatic stress disorders. He has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}